Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06588491 · ClinicalTrials.gov registry record · Phase 2
KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome
A Phase 2 study of Stiff Person Syndrome and SPS, sponsored by Kyverna Therapeutics.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 3
- Study locations
NCT06588491 is a Phase 2 study of Stiff Person Syndrome and SPS that is active but no longer recruiting, run by Kyverna Therapeutics. The registered enrollment target is 25 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06588491, a Phase 2 study of Stiff Person Syndrome and SPS, is active but no longer recruiting, sponsored by Kyverna Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 3
- Study locations
Study Summary
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome
Conditions Studied
Interventions
- BIOLOGICAL Standard lymphodepletion regimen
Study Locations (3)
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Minnesota
- Mayo Clinic - Rochester
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-09-25 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06588491
The ClinicalTrials.gov registry entry for NCT06588491 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kyverna Therapeutics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Stiff Person Syndrome appearing as the primary indexed condition, and to 1 intervention - of which Standard lymphodepletion regimen is the first listed.
NCT06588491 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Minnesota, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT06588491 about?
NCT06588491 is a clinical study titled "KYSA-8: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Treatment Refractory Stiff Person Syndrome". A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Subjects with Treatment Refractory Stiff Person Syndrome
What is the current status of trial NCT06588491?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-09-25. Estimated completion is 2026-12.
What conditions does trial NCT06588491 study?
This clinical trial studies the following conditions: Stiff Person Syndrome, SPS.
What interventions are being tested in trial NCT06588491?
The interventions under investigation include: Standard lymphodepletion regimen (BIOLOGICAL).
Who is sponsoring clinical trial NCT06588491?
This trial is sponsored by Kyverna Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06588491 being conducted?
This trial has 3 study locations across Colorado, Minnesota, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stiff Person Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.